Advocating for a world where intellectual
property law serves the public interest.
PhRMA’s Special 301 comments to the U.S. Trade Representative include a section on the compulsory licensing provisions in India’s Patents Act. PhRMA recommends that “India should ensure that the CL provisions comply with TRIPS by… Eliminating price as a trigger to CL. (Section 84(1)(b) of the Indian Patent Act which would permit a CL if […]
On March 27, the European Parliament’s International Trade Committee (INTA) voted 21-5 to reject a request by MEP David Martin to refer the Anticounterfeiting Trade Agreement to the European Court of Justice. Martin wanted the Court to determine whether or not the agreement conflicts with EU law. The INTA will instead conduct its own ACTA […]
As the TPP heads for its next intersessional meeting on IP provisions in April, public concern about the agreement has been growing, often tied to the previous public outcry over SOPA/PIPA and ACTA. The enforcement provisions in the IP section of the TPP have been described as “ACTA-plus,” but to what extent is the TPP […]
U.S. Commerce Secretary John Bryson criticized India’s recent compulsory license for the anticancer drug Nexaver in a meeting with Indian Minister of Commerce Anand Sharma. A government official told the Economic Times that “Bryson said pharmaceuticals was a competitive area and heavy investments went into R&D every year. Any dilution of the international patent regime […]
Infojustice Roundup Intellectual Property and the Public Interest Federal Research Public Access Act attracts two dozen additional co-sponsors Twenty four additional Representatives have cosponsored the Federal Research Public Access Act, (FPRAA, H.R.4004), introduced by Rep. Doyle on February 9. The bill would require Federal Agencies to collect digital copies of peer-reviewed journal articles that result […]
On Wednesday, the Indian Supreme Court will hear arguments in Novartis’ challenge to India’s patent law. In 2006, the Indian Patent Office rejected Novartis’ patent application for the cancer drug Glivec (imatinib mesylate), saying that the drug was a new salt formulation of a known drug, and therefore unpatentable under Indian Law. Section 3(d) of […]
Posts by Category
- Video
- User Rights Network
- US Domestic Policies
- US Domestic Legislation
- Transparency
- Trade Agreements
- Takedown
- Trade Disputes
- Trademark
- Round-up
- Regional Fora
- Surveys and Data
- Positive Agenda
- Patent Pledges
- Open
- News
- Multilateral Fora
- Limitations and Exceptions
- IP & Research
- IP and Human Rights
- Industry Initiatives
- Flagged
- Fair Use
- Events
- Empirical Research
- Document Library
- Coronavirus
- Brazil
- Blog
- Bilateral Trade Pressures
- Artificial Intelligence
- AI
- Africa Group Work Plan Proposal
- Africa: Copyright & Public Interest
- Access to Medicine
- Academic Resources